Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
Stopped The original sponsor was acquired by a new company and has elected to end funding for all Investigator Sponsored Trials (ISTs)
Conditions
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- DRUG: Alvocidib Hydrochloride
- DRUG: Decitabine
- DRUG: Venetoclax
Sponsor
M.D. Anderson Cancer Center
Collaborators